ClinicalTrials.gg
CompletedNCT01204398Updated Jun 27, 2014Results posted

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

A Phase 3 interventional study of telmisartan+amlodipine fixed dose combination in Hypertension, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
91st of 99
27 · median 184
Started
2010
with 5 others
Phase 3
40 of 99
none open now
Registered
42nd of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 91st largest by enrollment, is one of 6 that started in 2010, is one of 40 in phase 3, and was the 42nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The primary objectives of this trial is to evaluate the changes from baseline (Visit 2) in the 24-hour Ambulatory Blood Pressure Monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with Telmisartan 80mg/Amlodipine 5mg in patients with moderate to severe hypertension

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged at least 18 years at the date of signing the consent form
  2. For treatment-naïve patients: hypertension defined by a mean seated diastolic blood pressure (DBP) equal or more than 100 mmHg measured by manual cuff sphygmomanometry at visit 1 and 2; For pretreatment patients: hypertension defined by a mean seated diastolic blood pressure equal or more than 90 mmHg at visit 1 and equal or more than 100 mmHg at visit 2 measured by manual cuff sphygmomanometry
  3. 24-hour mean diastolic blood pressure equal or more than 85 mmHg at baseline Ambulatory Blood Pressure Monitoring

Exclusion criteria

Exclusion criteria:

  1. mean seated systolic blood pressure equal or more than 200 mmHg and/or mean seated diastolic blood pressure equal or more than 120 mmHg
  2. any hepatic impairment
  3. severe renal impairment
  4. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant
  5. current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped
  6. other conditions or situations that could put potential participants at unacceptable risk due to participation in this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    eligible hypertension patient

    Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.

    Drug: telmisartan+amlodipine fixed dose combination

Interventions

06

What researchers measure

Primary outcomes

  1. DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean

    ABPM measurements were taken every 20 minutes throughout the day and night by the validated SpaceLabs Model 90217 monitor.

    Time frame: 8 weeks

Secondary outcomes

  1. Change From Baseline in ABPM Hourly Mean DBP and SBP, Starting 1 Hour After Dosing

    Changes from baseline in DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM after 8 weeks of treatment with T80/A5

    Time frame: 8 weeks

  2. Trough to Peak (T/P) Ratio for DBP and SBP After 8 Weeks of Treatment

    Calculated on the basis of changes in hourly means from baseline. Trough is defined as the mean of the last three hours of the 24-hour dosing interval. Peak is the greatest reduction in hourly means in hours 2 to 8 after dosing. All measurements are using ABPM.

    Time frame: 8 weeks

  3. Change From Baseline to End of Study in DBP and SBP

    Manually measured in-clinic DBP and SBP

    Time frame: 8 weeks

  4. ABPM Hourly Mean DBP and SBP at Baseline and the End of the Study, Starting 1 Hour After Dosing

    DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM at baseline and after 8 weeks of treatment

    Time frame: 0 and 8 weeks

  5. Treatment Emergent Adverse Events

    Electrocardiogram, laboratory parameters and physical examinations were performed and any abnormal findings were recorded within the adverse events

    Time frame: 8 weeks

  6. Change From Baseline to End of Study in In-clinic Pulse Rate

    Time frame: 8 weeks

07

Results

Posted Aug 24, 2012

Participant flow

Participant flow — Overall Study
MilestoneT80/A5
Started27
Completed26
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryDBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean

ABPM measurements were taken every 20 minutes throughout the day and night by the validated SpaceLabs Model 90217 monitor.

Time frame:
8 weeks
Reported as:
Mean · mmHg
DBP and SBP Change From Baseline in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean
mmHgT80/A5
DBP change from baseline-12.76 ± 7.42
SBP change from baseline-23.82 ± 14.54
SecondaryChange From Baseline in ABPM Hourly Mean DBP and SBP, Starting 1 Hour After Dosing

Changes from baseline in DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM after 8 weeks of treatment with T80/A5

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change From Baseline in ABPM Hourly Mean DBP and SBP, Starting 1 Hour After Dosing
mmHgT80/A5
DBP Change from baseline after 1 hour-12.5 ± 10.7
DBP Change from baseline after 2 hours-14.7 ± 14.2
DBP Change from baseline after 3 hours-13.7 ± 13.9
DBP Change from baseline after 4 hours-11.7 ± 10.9
DBP Change from baseline after 5 hours-9.9 ± 15.6
DBP Change from baseline after 6 hours-11.7 ± 13.4
DBP Change from baseline after 7 hours-15.9 ± 12.3
DBP Change from baseline after 8 hours-14.8 ± 9.2
DBP Change from baseline after 9 hours-13.7 ± 11.1
DBP Change from baseline after 10 hours-12.9 ± 13.3
DBP Change from baseline after 11 hours-13.6 ± 13.0
DBP Change from baseline after 12 hours-13.1 ± 12.5
DBP Change from baseline after 13 hours-13.2 ± 12.4
DBP Change from baseline after 14 hours-11.9 ± 14.8
DBP Change from baseline after 15 hours-11.5 ± 12.8
DBP Change from baseline after 16 hours-11.8 ± 18.3
DBP Change from baseline after 17 hours-12.6 ± 14.0
DBP Change from baseline after 18 hours-13.1 ± 12.2
DBP Change from baseline after 19 hours-11.8 ± 10.6
DBP Change from baseline after 20 hours-10.7 ± 13.2
DBP Change from baseline after 21 hours-9.0 ± 13.4
DBP Change from baseline after 22 hours-13.8 ± 15.8
DBP Change from baseline after 23 hours-13.9 ± 9.8
DBP Change from baseline after 24 hour-14.8 ± 12.1
SBP Change from baseline after 1 hour-25.0 ± 21.3
SBP Change from baseline after 2 hours-26.2 ± 22.7
SBP Change from baseline after 3 hours-30.1 ± 26.3
SBP Change from baseline after 4 hours-21.9 ± 20.3
SBP Change from baseline after 5 hours-23.9 ± 19.7
SBP Change from baseline after 6 hours-23.9 ± 22.6
SBP Change from baseline after 7 hours-29.2 ± 18.8
SBP Change from baseline after 8 hours-27.6 ± 18.0
SBP Change from baseline after 9 hours-27.7 ± 21.1
SBP Change from baseline after 10 hours-25.8 ± 20.2
SBP Change from baseline after 11 hours-22.8 ± 20.4
SBP Change from baseline after 12 hours-23.4 ± 19.2
SBP Change from baseline after 13 hours-22.4 ± 19.5
SBP Change from baseline after 14 hours-22.1 ± 20.8
SBP Change from baseline after 15 hours-22.9 ± 19.4
SBP Change from baseline after 16 hours-24.4 ± 22.5
SBP Change from baseline after 17 hours-23.3 ± 19.9
SBP Change from baseline after 18 hours-21.7 ± 22.2
SBP Change from baseline after 19 hours-21.2 ± 16.8
SBP Change from baseline after 20 hours-20.5 ± 21.2
SBP Change from baseline after 21 hours-17.0 ± 24.6
SBP Change from baseline after 22 hours-19.2 ± 25.8
SBP Change from baseline after 23 hours-24.6 ± 15.6
SBP Change from baseline after 24 hour-25.1 ± 16.9
SecondaryTrough to Peak (T/P) Ratio for DBP and SBP After 8 Weeks of Treatment

Calculated on the basis of changes in hourly means from baseline. Trough is defined as the mean of the last three hours of the 24-hour dosing interval. Peak is the greatest reduction in hourly means in hours 2 to 8 after dosing. All measurements are using ABPM.

Time frame:
8 weeks
Reported as:
Median · Ratio
Trough to Peak (T/P) Ratio for DBP and SBP After 8 Weeks of Treatment
RatioT80/A5
DBP T/P ratio (N=23)1.13 ± -14.9, 15.8
SBP T/P ratio (N=25)0.98 ± -7.6, 14.0
SecondaryChange From Baseline to End of Study in DBP and SBP

Manually measured in-clinic DBP and SBP

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change From Baseline to End of Study in DBP and SBP
mmHgT80/A5
DBP: Change from baseline to 2 weeks-9.67 ± 7.14
DBP: Change from baseline to 4 weeks-13.49 ± 7.22
DBP: Change from baseline to 8 weeks-13.73 ± 6.58
SBP: Change from baseline to 2 weeks-11.04 ± 8.99
SBP: Change from baseline to 4 weeks-17.95 ± 10.53
SBP: Change from baseline to 8 weeks-19.80 ± 9.96
SecondaryABPM Hourly Mean DBP and SBP at Baseline and the End of the Study, Starting 1 Hour After Dosing

DBP and SBP hourly means over the 24-hour dosing interval as measured by ABPM at baseline and after 8 weeks of treatment

Time frame:
0 and 8 weeks
Reported as:
Mean · mmHg
ABPM Hourly Mean DBP and SBP at Baseline and the End of the Study, Starting 1 Hour After Dosing
mmHgT80/A5
DBP after 1 hour at baseline101.6 ± 10.2
DBP after 2 hours at baseline101.7 ± 13.2
DBP after 3 hours at baseline100.0 ± 11.1
DBP after 4 hours at baseline97.9 ± 9.5
DBP after 5 hours at baseline95.3 ± 11.3
DBP after 6 hours at baseline96.5 ± 11.6
DBP after 7 hours at baseline97.0 ± 12.6
DBP after 8 hours at baseline100.6 ± 9.8
DBP after 9 hours at baseline102.7 ± 10.3
DBP after 10 hours at baseline100.4 ± 11.2
DBP after 11 hours at baseline97.9 ± 11.8
DBP after 12 hours at baseline95.9 ± 11.0
DBP after 13 hours at baseline93.6 ± 11.8
DBP after 14 hours at baseline92.0 ± 11.5
DBP after 15 hours at baseline89.4 ± 11.9
DBP after 16 hours at baseline89.1 ± 16.8
DBP after 17 hours at baseline88.0 ± 10.4
DBP after 18 hours at baseline88.8 ± 11.6
DBP after 19 hours at baseline88.4 ± 10.3
DBP after 20 hours at baseline90.3 ± 12.9
DBP after 21 hours at baseline91.4 ± 10.4
DBP after 22 hours at baseline97.6 ± 14.2
DBP after 23 hours at baseline101.0 ± 10.0
DBP after 24 hours at baseline101.8 ± 9.3
DBP after 1 hour at the end of the study89.1 ± 8.5
DBP after 2 hours at the end of the study87.1 ± 11.0
DBP after 3 hours at the end of the study86.3 ± 11.1
DBP after 4 hours at the end of the study86.2 ± 10.1
DBP after 5 hours at the end of the study85.3 ± 10.2
DBP after 6 hours at the end of the study84.8 ± 11.4
DBP after 7 hours at the end of the study81.1 ± 12.8
DBP after 8 hours at the end of the study85.8 ± 7.5
DBP after 9 hours at the end of the study88.9 ± 9.7
DBP after 10 hours at the end of the study87.5 ± 10.5
DBP after 11 hours at the end of the study84.3 ± 9.6
DBP after 12 hours at the end of the study82.8 ± 9.1
DBP after 13 hours at the end of the study80.4 ± 10.2
DBP after 14 hours at the end of the study80.1 ± 13.6
DBP after 15 hours at the end of the study77.9 ± 11.4
DBP after 16 hours at the end of the study77.3 ± 8.9
DBP after 17 hours at the end of the study75.5 ± 11.2
DBP after 18 hours at the end of the study75.7 ± 11.5
DBP after 19 hours at the end of the study76.6 ± 9.7
DBP after 20 hours at the end of the study79.6 ± 10.4
DBP after 21 hours at the end of the study82.4 ± 10.5
DBP after 22 hours at the end of the study83.8 ± 12.5
DBP after 23 hours at the end of the study87.2 ± 10.4
DBP after 24 hours at the end of the study87.0 ± 12.4
SBP after 1 hour at baseline157.9 ± 17.9
SBP after 2 hours at baseline156.5 ± 20.1
SBP after 3 hours at baseline158.4 ± 21.4
SBP after 4 hours at baseline152.6 ± 15.9
SBP after 5 hours at baseline152.1 ± 21.1
SBP after 6 hours at baseline152.6 ± 24.6
SBP after 7 hours at baseline154.6 ± 23.3
SBP after 8 hours at baseline157.3 ± 19.6
SBP after 9 hours at baseline161.0 ± 18.6
SBP after 10 hours at baseline157.6 ± 20.2
SBP after 11 hours at baseline153.3 ± 21.8
SBP after 12 hours at baseline150.0 ± 20.8
SBP after 13 hours at baseline145.8 ± 22.2
SBP after 14 hours at baseline146.3 ± 22.7
SBP after 15 hours at baseline141.9 ± 23.9
SBP after 16 hours at baseline142.2 ± 26.2
SBP after 17 hours at baseline139.6 ± 19.1
SBP after 18 hours at baseline137.8 ± 22.9
SBP after 19 hours at baseline139.2 ± 20.5
SBP after 20 hours at baseline142.2 ± 21.6
SBP after 21 hours at baseline143.6 ± 20.6
SBP after 22 hours at baseline148.5 ± 22.2
SBP after 23 hours at baseline156.6 ± 18.9
SBP after 24 hours at baseline158.2 ± 16.6
SBP after 1 hour at the end of the study132.8 ± 15.0
SBP after 2 hours at the end of the study130.2 ± 15.3
SBP after 3 hours at the end of the study128.3 ± 17.9
SBP after 4 hours at the end of the study130.6 ± 17.8
SBP after 5 hours at the end of the study128.2 ± 19.1
SBP after 6 hours at the end of the study128.8 ± 17.3
SBP after 7 hours at the end of the study125.5 ± 19.4
SBP after 8 hours at the end of the study129.7 ± 15.5
SBP after 9 hours at the end of the study133.2 ± 16.8
SBP after 10 hours at the end of the study131.7 ± 17.3
SBP after 11 hours at the end of the study130.5 ± 17.8
SBP after 12 hours at the end of the study126.6 ± 15.9
SBP after 13 hours at the end of the study123.5 ± 15.8
SBP after 14 hours at the end of the study124.2 ± 19.9
SBP after 15 hours at the end of the study119.1 ± 14.6
SBP after 16 hours at the end of the study117.8 ± 14.6
SBP after 17 hours at the end of the study116.4 ± 16.0
SBP after 18 hours at the end of the study116.1 ± 18.4
SBP after 19 hours at the end of the study118.0 ± 17.8
SBP after 20 hours at the end of the study121.7 ± 19.0
SBP after 21 hours at the end of the study126.6 ± 18.3
SBP after 22 hours at the end of the study129.3 ± 21.5
SBP after 23 hours at the end of the study132.0 ± 16.6
SBP after 24 hours at the end of the study133.1 ± 20.2
SecondaryTreatment Emergent Adverse Events

Electrocardiogram, laboratory parameters and physical examinations were performed and any abnormal findings were recorded within the adverse events

Time frame:
8 weeks
Reported as:
Number · Participants
Treatment Emergent Adverse Events
ParticipantsT80/A5
Patients with any AEs4
Patients with severe AEs0
Patients with drug-related AEs1
Patients with AEs related to laboratory changes0
SecondaryChange From Baseline to End of Study in In-clinic Pulse Rate
Time frame:
8 weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline to End of Study in In-clinic Pulse Rate
beats per minute (bpm)T80/A5
Change From Baseline to End of Study in In-clinic Pulse Rate2.37 ± 5.95

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T80/A5—0/27 (0%)0/27 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)T80/A5
Mean52.0 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)T80/A5
Female8
Male17
Mean 24-hour mean Diastolic blood pressure (DBP)
Mean 24-hour mean Diastolic blood pressure (DBP)(mmHg)T80/A5
Mean95.79 ± 7.74
Mean 24-hour mean Systolic blood pressure (SBP)
Mean 24-hour mean Systolic blood pressure (SBP)(mmHg)T80/A5
Mean150.24 ± 17.30
08

Study locations

1 site
  • 1235.31.86001 Boehringer Ingelheim Investigational Site
    Shanghai, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2010
First posted
Sep 17, 2010
Start
Nov 2010
Primary completionActual
Jul 2011
Results first posted
Aug 24, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01204398
Responsible party
Sponsor
First posted
Sep 17, 2010
Start date
Nov 2010
Primary completion
Jul 2011
Results posted
Aug 24, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion